Professor, Psychiatry, Perelman School of Medicine
Psychiatry
Dr. Kyle M. Kampman, MD
|
|
Give Review
Doctor Kyle M. Kampman, MD is an expert in the field of Psychiatry. He attended Tulane University School of Medicine. He has 2 awards "America's Top Doctors" and "Philadelphia Magazine". Doctor Kyle M. Kampman, MD is also a published physician. He has 87 paper published. The most recent paper is: Reliability and validity of the Cocaine Selective Severity Assessment. Kyle Kampman accepts all Medicare patients.
Publications
- Insomnia in alcohol dependent subjects is associated with greater psychosocial problem severity.
- A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.
- Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial.
- Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cues.
- The Effects of Quetiapine on Sleep in Recovering Alcohol-Dependent Subjects: A Pilot Study.
- The Dopamine Receptor D2 (DRD2) SNP rs1076560 is Associated with Opioid Addiction.
- Buprenorphine Implants for Treatment of Opioid Dependence: Randomized Comparison to Placebo and Sublingual Buprenorphine/Naloxone.
- Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis.
- Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence.
- A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence.
- Case-control association study of WLS variants in opioid and cocaine addicted populations.
- Low frequency genetic variants in the ?-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine.
- Case-control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations.
- Reward-related Brain Response and Craving Correlates of Marijuana Cue Exposure: A Preliminary Study in Treatment-seeking Marijuana-dependent Subjects.
- A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence.
- Ventricular fibrillation during cardiopulmonary bypass: long-term effects on myocardial morphology and function.
- A detoxification dialogue.
- Bethanechol in the treatment of stuttering.
- Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence.
- Does modafinil produce euphoria?
- Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166)
- Modulation of resting brain cerebral blood flow by the GABA B agonist, baclofen: A longitudinal perfusion fMRI study.
- Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study.
- Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.
- Adding a nicotine blocking agent to cigarette tapering.
- DAT genotype modulates brain and behavioral responses elicited by cigarette cues.
- Outcome predictors in cocaine dependence treatment trials.
- Cocaine withdrawal symptoms identify "Type B" cocaine-dependent patients.
- The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.
- A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence.
- Cocaine abstinence symptomatology and treatment attrition.
- A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence.
- Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial.
- Open trials as a method of prioritizing medications for inclusion in controlled trials for cocaine dependence.
- The effects of naltrexone on alcohol and cocaine use in dually addicted patients.
- Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity.
- Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment.
- Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms.
- The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial.
- Reliability and validity of the Cocaine Selective Severity Assessment.
- Combination of the dopaminergic agent, phentermine, and the serotonergic agent, fenfluramine, in the treatment of cocaine dependence.
- Tolerance and sensitization to the effects of cocaine use in humans: a retrospective study of long-term cocaine users in Philadelphia.
- Expanding applications of deep brain stimulation: a potential therapeutic role in obesity and addiction management.
- Results of an initial clinical trial of varenicline for the treatment of cocaine dependence.
- Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis.
- New medications for the treatment of cocaine dependence.
- A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence.
- Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.
- Covariates of craving in actively drinking alcoholics.
- What's new in the treatment of cocaine addiction?
- A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.
- Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence.
- Amantadine treatment for cocaine-dependent patients with severe withdrawal symptoms.
- Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence.
- Association analysis between polymorphisms in the dopamine D3 receptor (DRD3) gene and cocaine dependence.
- Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependence.
- Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence.
- Early abstinence in cocaine pharmacotherapy trials predicts successful treatment outcomes.
- Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment.
- Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence.
- Study blinding and correlations between perceived group assignment and outcome in a cocaine pharmacotherapy trial.
- Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence.
- Genetic variants in the cocaine- and amphetamine-regulated transcript gene (CARTPT) and cocaine dependence.
- A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention.
- The search for medications to treat stimulant dependence.
- Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study.
- A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence.
- Why do those who request smoking treatment fail to attend the first appointment?
- Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence.
- A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism.
- The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
- No association between polymorphisms in the prostate apoptosis factor-4 gene and cocaine dependence.
- Analysis of variations in the tryptophan hydroxylase-2 (TPH2) gene in cocaine dependence.
- The status of disulfiram: a half of a century later.
- A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine with...
- A double-blind, placebo-controlled trial of modafinil for cocaine dependence.
- A pilot trial of topiramate for the treatment of cocaine dependence.
- Association of a polymorphism in the Homer1 gene with cocaine dependence in an African American population.
- Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence.
- Cocaine Rapid Efficacy Screening Trials (CREST): lessons learned.
- Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol.
- An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studies.
- A pilot trial of olanzapine for the treatment of cocaine dependence.
- Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.
- Concurrent cocaine withdrawal alters alcohol withdrawal symptoms.
- Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence.
Schools
Tulane University of Louisiana
University Penn College Med
Doctors Specialties
- Addiction Psychiatry
- Psychiatry
Accepted Insurances
Awards
- America's Top Doctors
- Philadelphia Magazine
Education
-
University of Pennsylvania Health System -
National Capital Consortium -
Tulane University School of Medicine
Hospital
-
Hospital of the University of Pennsylvania -
Penn Presbyterian Medical Center -
Philadelphia Veterans Affairs Medical Center
Drug Facts
| NPI NUMBER | 1093745085 | |
| NPPES Provider LastName | KAMPMAN | |
| NPPES Provider FirstName | KYLE | |
| NPPES Provider ZIPCode | 19104 | |
| NPPES Provider State | PA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 31.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1093745085 |
| Last Name Of The Provider | KAMPMAN |
| First Name Of The Provider | KYLE |
| View All |
Similar Doctors
|
|
Dr. James M. Pedigo, MD |
|
|
Dr. James J. Yi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sandra G. Gascon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Quratulain Agha, MD |
|
|
Dr. Daniel J. Lache, MD |
|
|
Dr. William M. Uffner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ellen Gluzman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James A. Peightel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alan R. Sandman, MD |
|
|
Dr. Vasant P. Dhopesh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William Jangro, DO
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jonathan A. Beatty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew M. Stone, MD |
|
|
Dr. Thomas B. Richardson, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard F. Limoges, MD
This Doctor is OpenDoctor Recommended.
|